Bayer chief revives Agfa speculation

Article

Call it the rumor that refused to die. The chairman of Agfa parentBayer has again renewed speculation that the German pharmaceuticalgiant is planning to spin off Agfa into an independent company.In an interview with the German press, Manfred Schneider

Call it the rumor that refused to die. The chairman of Agfa parentBayer has again renewed speculation that the German pharmaceuticalgiant is planning to spin off Agfa into an independent company.In an interview with the German press, Manfred Schneider repeatedstatements made last year that Agfa's profitability is too lowand that Bayer may divest the company in the next several years.

On two occasions last year, Schneider told reporters that therewere few synergies between Bayer and Agfa, because Bayer is apharmaceutical and chemical company and Agfa is moving into digitalimaging, and that Bayer might be interested in selling or divestingAgfa.

Schneider made comments earlier this year that seemed to putthe matter to rest, however, saying that Bayer had no intentionof divesting Agfa (SCAN 2/28/96). He apparently reversed himselflast month, again stating that Agfa's 3% profit margin is toolow compared with the 10% margin the Bayer group is targeting,according to AFX News.

Schneider and Bayer CFO Helmut Loehr said that Bayer would workto improve Agfa's profitability and will decide whether to divestthe company next year. A sale is not likely, due to antitrustconcerns and the probable difficulty in finding a buyer at a priceBayer would find acceptable.

Schneider's most recent comments are nothing new, said DionnTron, Agfa vice president of corporate communications.

"I think that the comments he made were an update on (thesituation). There aren't any intentions to sell Agfa; going publicremains an option," Tron said. "We've been asked toimprove our profitability. We've been working to do that, andwe're beginning to see the results of that effort."

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.